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Abstract
Background
Malignant ameloblastoma, comprising metastasizing ameloblastoma and ameloblastic car-
cinoma, represents 1.6–2.2% of all odontogenic tumors. Due to its rare nature, malignant
ameloblastoma has only been reported in the literature in small case series or case reports.
Using the Surveillance, Epidemiology and End-Results (SEER) database, we have per-
formed a population-based study to determine the incidence rate and the absolute survival
of malignant ameloblastoma.
Method
Using the International Classification of Diseases for Oncology (ICD-O) codes 9310/3 and
9270/3, data from the SEER database were used to calculate the incidence rate and abso-
lute survival rate of population with malignant ameloblastoma.
Results
The overall incidence rate of malignant ameloblastoma was 1.79 per 10 million person/
year. The incidence rate was higher in males than females and also higher in black versus
white population. The median overall survival was 17.6 years from the time of diagnosis and
increasing age was associated with a statistically significant poorer survival.
Conclusions
To our best knowledge, we report the largest population-based series of malignant amelo-
blastoma. The incidence rate was 1.79 per 10 million person/year and the overall survival
was 17.6 years.
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Introduction
Benign ameloblastoma is the second most common odontogenic tumor that is histologically
benign, but locally aggressive [1]. In contrast, malignant ameloblastoma is rare and constitutes
1.6–2.2% of all odontogenic tumors [2–4]. After decades of controversy [5,6], the World Health
Organization (WHO) classified malignant ameloblastoma into two types: metastasizing amelo-
blastoma and ameloblastic carcinoma[7]. Metastasizing ameloblastoma histologically resem-
bles the benign ameloblastoma but demonstrates metastatic spread to distant sites.
Ameloblastic carcinoma exhibits malignant histological features and can be further divided
into two subtypes: primary and secondary. Primary ameloblastic carcinoma arises de novo,
while secondary ameloblastic carcinomas are a result of malignant transformation of a previ-
ously diagnosed benign ameloblastoma. In this article, the term ‘malignant ameloblastoma’
will refer to metastazing ameloblastomas and ameloblastic carcinoma together. Malignant
ameloblastomas have only been reported in small case series or case reports and no popula-
tion-based studies of its incidence have been reported. Metastasizing ameloblastoma is often
considered to account for 2% of benign ameloblastoma[8], but the actual incidence rate is likely
to be less[9]. The exact incidence rate of ameloblastic carcinoma is unknown and only approxi-
mately 100 cases have been reported in the literature[10].
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer
Institute is a population-based cancer database covering approximately 28% of the United
States (US) population and collects epidemiological information of patients with cancer.
In this study, we have extracted the incidence rate and absolute survival from 293 malignant
ameloblastoma cases reported in the SEER database. To our knowledge, this is the largest series
of malignant ameloblastomas analyzed and the first report of incidence rate.
Methods
The Surveillance, Epidemiology and End Results (SEER) Database
A case listing session was opened in the SEER database. Our search parameters included the
SEER 18 Regs Research Data + hurricane Katrina Impacted Louisiana Cases, Nov 2013 sub
(1973–2011 varying) and the International Classification of Diseases for Oncology (ICD-O)
codes 9310/3 (metastasizing ameloblastomas) and 9270/3(ameloblastic carcinomas). For analy-
sis, we utilized the age groups recommended from the Adolescent and Young Adult Oncology
(AYAO) Progress Review Group: children (0–15 years old), young adults (16–39), adults (40–
64), and elderly (65)[11]. The treatments recorded are only those which were offered to the
patient at diagnosis.
Incidence Rate
Incidence rates and confidence intervals (CI) were obtained from the SEER 9 registries. Inci-
dence rates were age-standardized to the US standard population in 2000, which is the latest
standard population released by SEER for use with the SEERstat software. Incidence rate ra-
tios were used to measure the effect size of variables on the incidence rate. Unsmoothed age-
standardized rates were presented in tables and smoothed estimates were plotted on graphs.
Moving averages with a 4, 1, and 4 window were used in order to reduce random fluctuation.
This provided a clearer view of the underlying behavior of the data. The incidence rate ratio
(IRR) represents the incidence rate per unit of population (10 millions) of the age or race cate-
gory divided by the incidence rate of the base.
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Overall Survival
Survival data were obtained from the SEER 18 registries. Survival was defined as time from di-
agnosis until death due to all causes (overall survival). Kaplan–Meier estimates of survival were
calculated and the logrank test used to determine survival differences between the age groups.
Cox proportional hazards regression was used to calculate hazard ratios.
Statistical Analysis
All statistical analyses were performed with Stata software (Version 13; StataCorp, College Sta-
tion, TX). To describe the patient cohort, simple proportions were used along with Pearson’s
chi-squared test to identify significant imbalances. Multivariable modeling was performed
using forced entry methods as these methods are likely superior to stepwise and other sequen-
tial entry/exit methods [12]. Poisson regression was used to analyse the statistical significance
of age-adjusted incidence rate differences per gender. Type I error was 0.05 for all tests. P-val-
ues less than 0.05 were deemed significant.
Results
Study Cohort
The extraction from the SEER 18 registries yielded 293 patients with a median age of 52 years
(interquartile range 31). The characteristics of the patients included in this analysis are summa-
rized in Table 1. There were significantly more males than females diagnosed with malignant
ameloblastoma (62% of the cohort) and white ethnicity constituted 66% of the study group.
There was an imbalance in the site of disease affected depending on the patient’s age: in 75% of
children and young adults, the malignant lesion was found in the “bones of skull”, which most
likely indicates the maxilla. In contrast, the mandible was the most commonly affected area in
the elderly (41%). Regarding treatment, surgical excision was the most common mode of thera-
py (89%) followed by radiotherapy (15%).
Incidence
The overall incidence rate of malignant ameloblastoma was 1.79 per 10 million person/year
(Table 2). Both incidence rates and rate ratios increased with age. Children and young adults
were affected at a rate of 0.84 per 10 million person/year; adults, 2.5 per 10 million person/year
and elderly, 4.4 per 10 million person/year. In the male population, the incidence rate was 2.27
per 10 million person/year and in female, 1.42. As a result, the incidence rate ratio was 1.59
males affected for every female. The incidence rate was also significantly higher in the black
population than in the white. Fig. 1A showed how the difference in the incidence rates for
males and females was dependent on the age at diagnosis, with the sex differences becoming
apparent as age increased, rather than being homogenous throughout the ages. Nevertheless,
this apparent difference was not statistically significant.
Survival
Overall, the median survival was 17.6 years and was not significantly affected by sex or race
(Table 3). Children and young adults fared the best with 89% survival at 10 years and a relative-
ly flat survival curve (Fig. 1B). In contrast, the elderly had the poorest percentage of survivors
at 10 years (60%) and the shortest median survival (6.6 years). Moreover, the elderly popula-
tion was 9.6 (95% CI 5–18.1) times as likely to die as the young adult population after adjusting
for multiple confounders (but not accounting for background mortality). This resulted in the
steepest survival curve of all age groups (Fig. 1B).
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Table 1. Baseline characteristics of patients.
Children and
young adults
Adults Elderly Total P-value
No % No % No % No %
Total 89 30 115 40 89 30 293 100 -
Sex
Male 46 52 81 70 54 61 181 62 0.023
Female 43 48 34 30 35 39 112 38
Year of diagnosis
1973–1984 7 8 14 12 11 12 32 11 0.176
1985–1994 19 21 15 13 13 15 47 16
1995–2004 37 42 38 33 40 45 115 39
2005–2013 26 29 48 42 25 28 99 34
Site
Bones of skull 67 75 73 63 42 47 182 62 0.003
Mandible 19 22 31 27 36 41 86 29
Other sites 3 3 11 10 11 12 25 9
Race
White 45 51 83 72 66 74 194 66 0.004
Black 28 31 20 17 18 20 66 23
Other or unknown 16 18 12 10 5 6 33 11
Radiation
None, refused or unknown 82 92 98 85 69 78 249 85 0.024
Radiation 7 8 17 15 20 22 44 15
Treatment
No surgery 3 3 14 12 16 18 33 11 0.008
Surgery 86 97 101 88 73 82 260 89
P-values obtained with Pearson chi-squared test.
doi:10.1371/journal.pone.0117789.t001
Table 2. Incidence rates and incidence rate ratios (IRR) per 10 million population.
Counts (%) Incidence rate (95% CI) IRR (95% CI)
Total 164 (100) 1.79 (1.53–2.09) 0.72 (0.54–0.96)
Children and young adults 48 (29) 0.84 (0.61–1.11)* 0.33 (0.22–0.49)
Adults 69 (42) 2.5 (1.95–0.32) Base
Elderly 47 (29) 4.4 (3.23–5.85)* 1.75 (1.18–2.58)
Female 69 (42) 1.42 (1.1–1.8) Base
Male 95 (58) 2.27 (1.83–2.78)* 1.59 (1.15–2.21)
White 108 (66) 1.46 (1.19–1.76) Base
Black 41 (25) 4.71 (3.32–6.47)* 3.2 (2.16–4.72)
Other 11 (7) 1.14 (0.57–2.08) 0.78 (0.37–1.48)
Unknown 4 (2) N/A N/A
Data obtained from SEER 9 registries.
* p<0.05.
N/A, not-applicable.
doi:10.1371/journal.pone.0117789.t002
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Using a univariate analysis, we showed that patients with malignant lesion to the “bones of
skull” or “other sites’ were respectively 1.7 and 2.3 times as likely to die as patients with man-
dibular lesions (Table 3). Interestingly, this did not show statistical significance using a multi-
variate approach (Table 4). It was difficult to assess the effect of a treatment (radiation or
surgery) on all-cause mortality despite being statistically significant because of the inherent se-
lection bias and lack of protocols dictating the administration of such therapies. The variables
were included in the final model as part of the forced-entry method.
An important negative finding on univariable and multivariable analysis was that sex and
race did not have survival differences: HR 1.01 (95%CI 0.66–1.55) for males compared to fe-
males and HR 1.17 (95%CI 0.7–1.97) for whites compared to black people (Table 4).
Fig 1. Incidence rate and overall survival. (a) Smoothed incidence rates (per 10 million) across patient
ages at diagnosis, by sex. (b) Kaplan-Meier curves and (c) smoothed hazard rates by age group.
doi:10.1371/journal.pone.0117789.g001
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Fig. 1C demonstrated a divergent hazard rate curves after 6 years of follow-up, indicative of
a fork-type covariate-by-follow-up interaction.
Discussion
Perusing the SEER data, our study demonstrated that the overall incidence rate of malignant
ameloblastoma was 1.79 per 10 million persons per year with male and black population pre-
dominance. The incidence rate increased as individual got older and elderly patients who re-
ceived a diagnosis of malignant ameloblastoma were nearly 10-times more likely to die than
children and young adults. Part of this increased HR in elderly could be explained by the in-
creasing background mortality or competing risks of death in this population. With what is
currently known about aging, it is reasonable to assume that a certain proportion of the effect
of age on mortality is due to confounding factors, such as age-associated diseases or decreased
physiological reserve found in the elderly population. More specifically, competing risks of
death are likely to have caused an over-estimation of the cumulative incidence of death and an
underestimation of overall survival related to this tumor [13]. Answering this question with ap-
propriate precision requires a larger sample size analyzed using the methods of relative survival
as used elsewhere [14–18].
The majority of malignant ameloblastomas occurred in males rather than females and this
results confirmed previous studies showing the male to female ratio to be between 2.3 and 5
Table 3. Overall survival.
% Survivors at _ years Median survival HR (95% CI) P-value
No 0.5 1 5 10 (years)
All 285 97 95 80 64 17.6 N/A N/A
Age group
Children & young adults 87 100 100 93 89 N/A Base N/A
Adults 110 98 97 85 65 22 2.9 (1.5–5.6) 0.002
Elderly 88 92 87 76 60 6.6 9.6 (5–18.1) <0.001
Sex
Female 109 97 96 78 66 18.6 Base N/A
Male 176 96 94 81 62 15 1.2 (0.8–1.8) 0.33
Race
Black 63 100 98 79 70 19.5 Base N/A
White 191 95 93 78 59 14.9 1.4 (0.8–2.3) 0.21
Other or unknown 31 100 96 92 86 23 0.6 (0.2–1.7) 0.35
Radiation
None, refused, unknown 241 97 96 84 69 18.9 Base N/A
Radiation 44 93 86 55 31 5.7 2.7 (1.7–4.2) <0.001
Treatment
No surgery 30 93 82 54 29 5.4 Base N/A
Underwent surgery 255 97 96 83 67 18.6 0.3 (0.2–0.6) <0.001
Site
Mandible 176 97 96 85 67 19.5 Base N/A
Bones of skull 84 97 95 75 62 13.6 1.7 (1.1–2.6) 0.016
Other sites 25 92 88 62 44 9.2 2.3 (1.3–4.3) 0.007
Univariate Cox proportional hazards ratio model. N/A: not applicable.
doi:10.1371/journal.pone.0117789.t003
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[10,19,20]. The cause for this increased incidence of malignant ameloblastomas in males com-
pared with females has not been investigated or reported, and remains unknown. The inci-
dence rate of developing a malignant ameloblastoma was higher in the black population. To
the best of our knowledge, this has never been reported before and merits further epidemiologi-
cal studies. Such race imbalance was suggested in 1978 by Shear and Singh, but their study only
concerned cases of benign ameloblastoma[21]. It remains to be explored if this difference is de-
termined by genetic or environment factors.
Our univariate (but not multivariate) analysis showed there was a significant increase in HR
for patient diagnosed with a malignant ameloblastoma affecting the “bones of skull” and “other
sites”. Ameloblastoma most commonly affects the mandible and maxilla, rarely other sites[22].
The SEER database only recorded the site of ameloblastomas as either the mandible or the
“bones of skull”. Hence, the latter was assumed to comprise mostly maxillary tumors. This re-
sults was surprising as the literature reports the mandible as the preferred site of disease devel-
opment [10,20,23]. However, most case reports published to date are from India, Japan and
China. It is thus possible that this anatomical distribution imbalance is a unique feature of the
U.S. population.
There is controversy regarding radiotherapy as a treatment option for ameloblastoma as it
is generally considered a radio-resistant tumor. One study reviewed ten patients with amelo-
blastomas treated with megavoltage irradiation and concluded that ameloblastoma was not an
inherently radio-resistant tumor and that properly applied megavoltage irradiation had a use-
ful role in the management[24]. However, there has not been any well-documented evidences
Table 4. Overall survival.
HR (95% CI) P-value
All N/A N/A
Age group
Children & young adults Base N/A
Adults 2.42 (1.22–4.76) 0.011
Elderly 7.71 (3.98–14.95) <0.001
Sex
Female Base N/A
Male 1.01 (0.66–1.55) 0.08
Race
Black Base N/A
White 1.17 (0.7–1.97) 0.54
Other or unknown 0.84 (0.31–2.31) 0.75
Radiation
None, refused, unknown Base N/A
Radiation 2.26 (1.42–3.6) 0.001
Treatment
No surgery Base N/A
Underwent surgery 0.45 (0.25–0.8) 0.006
Site
Mandible Base N/A
Bones of skull 1.2 (0.77–1.85) 0.42
Other sites 1.68 0.1
Multivariate Cox proportional hazards ratio model. N/A: not applicable.
doi:10.1371/journal.pone.0117789.t004
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concerning the true radio-responsiveness of these tumors since that study, and some authors
have doubt on its effectiveness, unless the tumor is inoperable[25].
One of the limitations of our study is that the SEER data represents only a portion of the U.
S. population and may generate sampling bias. Previous studies demonstrated that people liv-
ing within the registries captured by the SEER are more affluent, have lower unemployment
rate, and are more urbanized[26]. Moreover, the benign ameloblastoma is known to be more
prevalent in Africa and Asia, and relatively infrequent amongst Caucasians [27–29]. Whether
this is true for malignant ameloblastomas remains to be demonstrated. Another limitation of
utilizing the SEER data for rare tumor studies is that there was no central pathology review to
validate the diagnosis. However, the SEER Program is still considered one of the most compre-
hensive nationwide databases and the data is frequently utilized by investigators worldwide for
peer-reviewed publications[30].
For the purpose of our study, we did not separate malignant ameloblastoma into its two
subtypes (metastasizing ameloblastoma and ameloblastic carcinoma). Individually, metastasiz-
ing ameloblastoma (n = 184) and ameloblastic carcinoma (n = 109) did not record a sufficient
number to allow sound statistical analysis and survival modeling.
Finally, we demonstrated a divergent hazard rate curves after 6 years of follow-up, indicative
of a fork-type covariate-by-follow-up interaction (formal testing not done due to sample size
limitations) [16]. This was an indication that hazards were no longer proportional after 6 years
of follow-up and thus our interpretation of the Cox-proportional hazards model (hazard ra-
tios) must be limited to 6 years. This could partly be due to disease characteristics, physiologic
reserve or most likely the increased expected mortality as the elderly person ages.
Conclusion
To our best knowledge, we report here the largest series of malignant ameloblastomas in the lit-
erature and demonstrate its overall incidence rate as 1.79 per 10 million persons per year with
male and black population predominance.
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